The estimated Net Worth of William Roland Mann is at least $475 Thousand dollars as of 30 March 2022. Dr Mann owns over 6,200 units of NeuBase Therapeutics stock worth over $4,234 and over the last 4 years he sold NBSE stock worth over $0. In addition, he makes $470,398 as Chief Operating Officer at NeuBase Therapeutics.
Dr has made over 2 trades of the NeuBase Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 6,200 units of NBSE stock worth $11,904 on 30 March 2022.
The largest trade he's ever made was buying 6,200 units of NeuBase Therapeutics stock on 30 March 2022 worth over $11,904. On average, Dr trades about 2,240 units every 68 days since 2020. As of 30 March 2022 he still owns at least 11,200 units of NeuBase Therapeutics stock.
You can see the complete history of Dr Mann stock trades at the bottom of the page.
Dr. William Roland Mann MBA, Ph.D. is the Chief Operating Officer at NeuBase Therapeutics.
As the Chief Operating Officer of NeuBase Therapeutics, the total compensation of Dr D at NeuBase Therapeutics is $470,398. There are 7 executives at NeuBase Therapeutics getting paid more, with Dietrich Stephan having the highest compensation of $3,677,280.
Dr D is 61, he's been the Chief Operating Officer of NeuBase Therapeutics since . There are 1 older and 9 younger executives at NeuBase Therapeutics. The oldest executive at NeuBase Therapeutics, Inc. is Franklyn Prendergast, 75, who is the Independent Director.
William's mailing address filed with the SEC is C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR, , PITTSBURGH, PA, 15219.
Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan, and Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics executives and other stock owners filed with the SEC include: